Activist investors filed five separate 13D positions in the last seventy-two hours, targeting companies with a combined market capitalization exceeding $30 billion. The names span industrial chemicals (Ashland), clinical genomics (GeneDX Holdings), digital banking software (Alkami Technology), commercial satellite imagery (Satellogic), and application performance monitoring (Dynatrace). None of the positions share an activist fund or sector thesis, which marks this as broad-based rather than thematic.

Ashland, the $4.2 billion specialty chemicals manufacturer, received a filing from an undisclosed investor seeking board representation and a review of the company's adhesives and coatings divestiture timeline. GeneDX Holdings, trading near $8.50 per share, saw a filing that references undervaluation of its exome sequencing contracts with health systems. Alkami Technology, which provides cloud-native core banking software to 280 credit unions and community banks, is now subject to a filing that questions its customer acquisition cost relative to annual recurring revenue growth. Satellogic, the Argentina-headquartered Earth observation operator with 36 satellites in low orbit, faces a filing focused on commercial contract disclosure and capital allocation. Dynatrace, the $16 billion application observability platform, received a filing that challenges its sales-and-marketing spend as a percentage of gross profit.

The simultaneity matters. Activist campaigns typically cluster when macro volatility is low and equity valuations compress without corresponding operational stress. These five companies share no industry, no underwriter, and no overlapping institutional base. What they share is mid-cap liquidity, boards with fewer than eight members, and trailing twelve-month enterprise value-to-revenue multiples between 2.1x and 5.3x—well below their three-year averages. The filings suggest activists are working a valuation-recovery thesis rather than a sector rotation.

Operators and allocators should watch for three follow-on developments. First, whether any of the five companies announce special committees within ten business days, which would indicate negotiation rather than contest. Second, whether additional 13G-to-13D amendments surface in the next two weeks, signaling coordinated positioning. Third, whether proxy advisory firms issue early guidance on the GeneDX and Satellogic situations, both of which trade below $10 per share and face higher retail ownership percentages than the other three.

The activism wave now spans seven verticals in twenty-one days. Ashland reports earnings April 29. Dynatrace reports May 7.